Combination cancer immunotherapies tailored to the tumour microenvironment

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · see citing works

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · see citing works

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · see citing works

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · see citing works

The future of immune checkpoint therapy

Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · see citing works

Neoantigens in cancer immunotherapy

Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783 · see citing works

Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer

Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M. J., Obenauf, A. C., Angell, H. K., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,390 · see citing works

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · see citing works

Nivolumab plus Ipilimumab in Advanced Melanoma

Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · see citing works

Molecular and genetic properties of tumors associated with local immune cytolytic activity

Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · see citing works

Coordinated regulation of myeloid cells by tumours

Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · see citing works

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · see citing works

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,373 · see citing works

Immunogenic Cell Death in Cancer Therapy

Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · see citing works

Calreticulin exposure dictates the immunogenicity of cancer cell death

Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216 · see citing works

The Consensus Coding Sequences of Human Breast and Colorectal Cancers

Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161 · see citing works

Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · see citing works

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis

Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874 · see citing works

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839 · see citing works

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · see citing works

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781 · see citing works

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463 · see citing works

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434 · see citing works

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324 · see citing works

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222 · see citing works

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182 · see citing works

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation

Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166 · see citing works

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157 · see citing works

The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence

Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144 · see citing works

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141 · see citing works

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · see citing works

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063 · see citing works

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874 · see citing works

Restoration of p53 function leads to tumour regression in vivo

Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · see citing works

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737 · see citing works

Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy

DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715 · see citing works

Adoptive immunotherapy for cancer: harnessing the T cell response

Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688 · see citing works

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,678 · see citing works

Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody

Dewan, M. Z., Galloway, A. E., Kawashima, N., Dewyngaert, J. K., Babb, J. S., Formenti, S. C., & Demaria, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0265 · Cited by 1,678 · see citing works

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

Rosenberg, S. A., Restifo, N. P., Yang, J. C.-H., Morgan, R. A., & Dudley, M. E. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2355 · Cited by 1,654 · see citing works

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647 · see citing works

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560 · see citing works

Classifying Cancers Based on T-cell Infiltration and PD-L1

Teng, M. W. L., Ngiow, S. F., Ribas, A., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0255 · Cited by 1,412 · see citing works

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2006) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,341 · see citing works

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

Dovedi, S. J., Adlard, A. L., Lipowska‐Bhalla, G., McKenna, C., Jones, S., Cheadle, E. J., Stratford, I. J., Poon, E., Morrow, M., Stewart, R. A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1258 · Cited by 1,316 · see citing works

Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors

De Palma, M., Venneri, M. A., Galli, R., Sergi, L. S., Politi, L. S., Sampaolesi, M., & Naldini, L. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.002 · Cited by 1,311 · see citing works

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients

Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307 · see citing works

Type I interferons in anticancer immunity

Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305 · see citing works

IL-2: The First Effective Immunotherapy for Human Cancer

Rosenberg, S. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1490019 · Cited by 1,297 · see citing works

Combination cancer immunotherapy and new immunomodulatory targets

Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294 · see citing works

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,285 · see citing works

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Royal, R. E., Levy, C. L., Turner, K. M., Mathur, A., Hughes, M. S., Kammula, U. S., Sherry, R. M., Topalian, S. L., Yang, J. C.-H., Lowy, I., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181eec14c · Cited by 1,266 · see citing works

Mutant MHC class II epitopes drive therapeutic immune responses to cancer

Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243 · see citing works

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

Akbay, E. A., Koyama, S., Carretero, J., Altabef, A. B., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,237 · see citing works

The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function

Johnston, R. J., Comps‐Agrar, L., Hackney, J. A., Yu, X., Huseni, M. A., Yang, Y., Park, S., Javinal, V., Chiu, H. H., Irving, B. A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.018 · Cited by 1,191 · see citing works

Immunogenic death of colon cancer cells treated with oxaliplatin

Tesnière, A., Schlemmer, F., Boige, V., Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apétoh, L., Barault, L., et al. (2009) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,177 · see citing works

Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy

Klug, F., Prakash, H., Huber, P. E., Seibel, T., Bender, N., Halama, N., Pfirschke, C., Voss, R. H., Timke, C., Umansky, L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.014 · Cited by 1,097 · see citing works

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

Chao, M. P., Alizadeh, A. A., Tang, C. Z., Myklebust, J. H., Varghese, B., Gill, S. I., Jan, M., Cha, A. C., Chan, C. K. F., Tan, B. T., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.044 · Cited by 1,095 · see citing works

Macrophage Regulation of Tumor Responses to Anticancer Therapies

De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079 · see citing works

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

Robbins, P. F., Lu, Y., El‐Gamil, M., Li, Y. F., Gross, C. A., Gartner, J. J., Lin, J., Teer, J. K., Cliften, P. F., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,074 · see citing works

Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift

Formenti, S. C., & Demaria, S. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,058 · see citing works

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042 · see citing works

RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

Su, F., Virós, A., Milagre, C. S., Trunzer, K., Bollag, G. E., Spleiss, O., Reis-Filho, J. S., Kong, X., Koya, R. C., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105358 · Cited by 1,038 · see citing works

Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells

Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C. M. T., Pryer, N., Daniel, D., Hwang, E. S., Rugo, H. S., & Coussens, L. M. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.006 · Cited by 1,008 · see citing works

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

Lynch, T. J., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Neal, J. W., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 999 · see citing works

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967 · see citing works

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma

Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1630 · Cited by 944 · see citing works

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A. A., Ledbetter, J. A., Hellström, K. E., Mittler, R. S., & Chen, L. (1997) · Nature Medicine · doi:10.1038/nm0697-682 · Cited by 899 · see citing works

Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 879 · see citing works

IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases

Teng, M. W. L., Bowman, E. P., McElwee, J. J., Smyth, M. J., Casanova, J., Cooper, A. M., & Cua, D. J. (2015) · Nature Medicine · doi:10.1038/nm.3895 · Cited by 877 · see citing works

The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures

Galon, J., Angell, H. K., Bedognetti, D., & Marincola, F. M. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.008 · Cited by 861 · see citing works

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

Selby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857 · see citing works

Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death

Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A., Chapman, D. C., Durchschlag, M., Joza, N., Pierron, G., van Endert, P., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.1 · Cited by 848 · see citing works

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

Ribas, A., Kefford, R. F., Marshall, M. A., Punt, C. J. A., Haanen, J. B. A. G., Mármol, M., Garbe, C., Gogas, H. J., Schachter, J., Linette, G. P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.6112 · Cited by 802 · see citing works

TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients

Chauvin, J.-M., Pagliano, O., Fourcade, J. J., Sun, Z., Wang, H., Sander, C., Kirkwood, J. M., Chen, T.-H. T., Maurer, M. F., Korman, A. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80445 · Cited by 785 · see citing works

Opportunities and challenges of radiotherapy for treating cancer

Schaue, D., & McBride, W. H. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.120 · Cited by 784 · see citing works

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

Liu, X., Pu, Y., Cron, K. R., Deng, L., Kline, J. P., Frazier, W. A., Xu, H., Peng, H., Fu, Y., & Xu, M. M. (2015) · Nature Medicine · doi:10.1038/nm.3931 · Cited by 770 · see citing works

A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells

Barsoum, I. B., Smallwood, C. A., Siemens, D. R., & Graham, C. H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0992 · Cited by 767 · see citing works

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0118 · Cited by 742 · see citing works

Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors

Duraiswamy, J., Kaluza, K. M., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4100 · Cited by 737 · see citing works

Hepatotoxicity with Combination of Vemurafenib and Ipilimumab

Ribas, A., Hodi, F. S., Callahan, M. K., Konto, C., & Wolchok, J. D. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1302338 · Cited by 713 · see citing works

VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses

Wang, L. L., Rubinstein, R., Lines, J. L., Wasiuk, A., Ahonen, C. L., Guo, Y., Lu, L., Gondek, D. C., Wang, Y., Fava, R. A., et al. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20100619 · Cited by 713 · see citing works

The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans

Brandt, C. S., Baratin, M., Yi, E. C., Kennedy, J. J., Gao, Z., Fox, B. A., Haldeman, B. A., Ostrander, C. D., Kaifu, T., Chabannon, C., et al. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090681 · Cited by 701 · see citing works

Macrophages and cancer: from mechanisms to therapeutic implications

Ostuni, R., Kratochvill, F., Murray, P. J., & Natoli, G. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.004 · Cited by 685 · see citing works

Tumor Immunotherapy Directed at PD-1

Ribas, A. (2012) · New England Journal of Medicine · doi:10.1056/nejme1205943 · Cited by 680 · see citing works

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

Zhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., et al. (2011) · Blood · doi:10.1182/blood-2010-10-310425 · Cited by 675 · see citing works

Immune parameters affecting the efficacy of chemotherapeutic regimens

Zitvogel, L., Kepp, O., & Kroemer, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.223 · Cited by 665 · see citing works

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

Wilmott, J. S., Long, G. V., Howle, J. R., Haydu, L. E., Sharma, R. N., Thompson, J. F., Kefford, R. F., Hersey, P., & Scolyer, R. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2479 · Cited by 651 · see citing works

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

Sharma, P., Wagner, K., Wolchok, J. D., & Allison, J. P. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3153 · Cited by 639 · see citing works

Evolving synergistic combinations of targeted immunotherapies to combat cancer

Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Perez‐Gracia, J. L., & Haanen, J. B. A. G. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3973 · Cited by 633 · see citing works

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

Romano, E., Kusio-Kobialka, M., Foukas, P. G., Baumgaertner, P., Meyer, C., Ballabeni, P., Michielin, O., Weide, B., Romero, P., & Speiser, D. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417320112 · Cited by 601 · see citing works

Immunological mechanisms of the antitumor effects of supplemental oxygenation

Hatfield, S. M., Kjaergaard, J., Lukashev, D., Schreiber, T. H., Belikoff, B., Abbott, R., Sethumadhavan, S., Philbrook, P., Ko, K., Cannici, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1260 · Cited by 600 · see citing works

Bevacizumab plus ipilimumab in patients with metastatic melanoma

Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0053 · Cited by 593 · see citing works

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survivalPreprint

Brown, S. D., Warren, R. M., Gibb, E. A., Martin, S. D., Spinelli, J. J., Nelson, B. H., & Holt, R. A. (2014) · Genome Research · doi:10.1101/gr.165985.113 · Cited by 589 · see citing works

Bispecific antibodies

Kontermann, R. E., & Brinkmann, U. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.008 · Cited by 585 · see citing works

Anti-TIM3 Antibody Promotes T Cell IFN-γ–Mediated Antitumor Immunity and Suppresses Established Tumors

Ngiow, S. F., von Scheidt, B., Akiba, H., Yagita∥, H., Teng, M. W. L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0096 · Cited by 575 · see citing works

From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer

Angell, H., & Galon, J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.03.004 · Cited by 574 · see citing works

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

Stagg, J., Divisekera, U., McLaughlin, N. M., Sharkey, J., Pommey, S., Denoyer, D., Dwyer, K. M., & Smyth, M. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908801107 · Cited by 570 · see citing works

Significance of M2-Polarized Tumor-Associated Macrophage in Pancreatic Cancer

Kurahara, H., Shinchi, H., Mataki, Y., Maemura, K., Noma, H., Kubo, F., Sakoda, M., Ueno, S., Natsugoe, S., & Takao, S. (2009) · Journal of Surgical Research · doi:10.1016/j.jss.2009.05.026 · Cited by 552 · see citing works

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

Weber, J. S., Kudchadkar, R. R., Yu, B., Gallenstein, D., Horak, C. E., Inzunza, H. D., Zhao, X., Martinez, A. J., Wang, W., Gibney, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4802 · Cited by 535 · see citing works

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response

Sznol, M., & Chen, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2234 · Cited by 529 · see citing works

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

Balachandran, V. P., Cavnar, M. J., Zeng, S., Bamboat, Z. M., Ocuin, L. M., Obaid, H., Sorenson, E. C., Popow, R., Ariyan, C. E., Rossi, F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2438 · Cited by 523 · see citing works

Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type

Gatalica, Z., Snyder, C., Maney, T., Ghazalpour, A., Holterman, D. A., Xiao, N., Overberg, P., Rose, I., Basu, G. D., Vranić, S., et al. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0654 · Cited by 522 · see citing works

Gene-engineered T cells for cancer therapy

Kershaw, M. H., Westwood, J. A., & Darcy, P. K. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3565 · Cited by 504 · see citing works

Tumour‐infiltrating T‐cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review

Nosho, K., Baba, Y., Tanaka, N., Shima, K., Hayashi, M., Meyerhardt, J. A., Giovannucci, E., Dranoff, G., Fuchs, C. S., & Ogino, S. (2010) · The Journal of Pathology · doi:10.1002/path.2774 · Cited by 502 · see citing works

CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

Loi, S., Pommey, S., Haibe‐Kains, B., Beavis, P. A., Darcy, P. K., Smyth, M. J., & Stagg, J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222251110 · Cited by 497 · see citing works

Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies

Weiskopf, K., Ring, A. M., Ho, C. C. M., Volkmer, J.-P., Levin, A. M., Volkmer, A. K., Özkan, E., Fernhoff, N. B., van de Rijn, M., Weissman, I. L., et al. (2013) · Science · doi:10.1126/science.1238856 · Cited by 493 · see citing works

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

Sznol, M., & Chen, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2063 · Cited by 490 · see citing works

The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions

Chan, C. J., Martinet, L., Gilfillan, S., Souza-Fonseca-Guimarães, F., Chow, M. T., Town, L., Ritchie, D. S., Colonna, M., Andrews, D. M., & Smyth, M. J. (2014) · Nature Immunology · doi:10.1038/ni.2850 · Cited by 488 · see citing works

Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs

Allard, B., Pommey, S., Smyth, M. J., & Stagg, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0545 · Cited by 459 · see citing works

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Beatty, G. L., Torigian, D. A., Chiorean, E. G., Saboury, B., Brothers, A., Alavi, A. A., Troxel, A. B., Sun, W., Teitelbaum, U. R., Vonderheide, R. H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1320 · Cited by 458 · see citing works

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

Bulliard, Y., Jolicoeur, R., Windman, M., Rue, S. M., Ettenberg, S. A., Knee, D. A., Wilson, N. S., Dranoff, G., & Brogdon, J. L. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20130573 · Cited by 446 · see citing works

CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune Suppression

Jin, D., Fan, J., Wang, L., Thompson, L. F., Liu, A., Daniel, B. J., Shin, T., Curiel, T. J., & Zhang, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3109 · Cited by 433 · see citing works

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

Dahan, R., Sega, E. I., Engelhardt, J., Selby, M., Korman, A. J., & Ravetch, J. V. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.004 · Cited by 410 · see citing works

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

Marabelle, A., Kohrt, H. E. K., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J. A., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64859 · Cited by 384 · see citing works

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1

Fourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Olive, D., Kuchroo, V., & Zarour, H. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2637 · Cited by 372 · see citing works

At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy

Callahan, M. K., & Wolchok, J. D. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212631 · Cited by 349 · see citing works

Blockade of A 2A receptors potently suppresses the metastasis of CD73 + tumors

Beavis, P. A., Divisekera, U., Paget, C., Chow, M. T., John, L. B., Devaud, C., Dwyer, K. M., Stagg, J., Smyth, M. J., & Darcy, P. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308209110 · Cited by 346 · see citing works

A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies

Schaefer, G., Haber, L., Crocker, L., Shia, S., Shao, L., Dowbenko, D. J., Tótpál, K., Wong, A., Lee, C. V., Stawicki, S. S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.003 · Cited by 341 · see citing works

TLR agonists: our best frenemy in cancer immunotherapy

Kaczanowska, S., Joseph, A. M., & Dávila, E. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1012501 · Cited by 340 · see citing works

From mice to humans: developments in cancer immunoediting

Teng, M. W. L., Galon, J., Fridman, W.-H., & Smyth, M. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80004 · Cited by 337 · see citing works

Bispecific antibodies for cancer therapy: The light at the end of the tunnel?

Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336 · see citing works

Radiation as an immunological adjuvant: current evidence on dose and fractionation

Demaria, S., & Formenti, S. C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00153 · Cited by 333 · see citing works

The Yin and Yang of Toll-like receptors in cancer

Pradère, J., Dapito, D. H., & Schwabe, R. F. (2013) · Oncogene · doi:10.1038/onc.2013.302 · Cited by 332 · see citing works

TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer

Sakuishi, K., Ngiow, S. F., Sullivan, J. M., Teng, M. W. L., Kuchroo, V. K., Smyth, M. J., & Anderson, A. C. (2013) · OncoImmunology · doi:10.4161/onci.23849 · Cited by 329 · see citing works

Biomolecular Network Reconstruction Identifies T-Cell Homing Factors Associated With Survival in Colorectal Cancer

Mlecnik, B., Tosolini, M., Charoentong, P., Kirilovsky, A., Bindea, G., Berger, A., Camus, M., Gillard, M., Bruneval, P., Fridman, W. H., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.10.057 · Cited by 328 · see citing works

Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis

Guidoboni, M., Gafà, R., Viel, A., Doglioni, C., Russo, A., Santini, A., Del Tin, L., Macrì, E., Lanza, G., Boiocchi, M., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61695-1 · Cited by 322 · see citing works

Ipilimumab and Its Toxicities: A Multidisciplinary Approach

Fecher, L. A., Agarwala, S. S., Hodi, F. S., & Weber, J. S. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0483 · Cited by 320 · see citing works

Targeting Cancer-Derived Adenosine:New Therapeutic Approaches

Young, A., Mittal, D., Stagg, J., & Smyth, M. J. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0341 · Cited by 312 · see citing works

IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma

Yang, Z., Grote, D. M., Ziesmer, S. C., Niki, T., Hirashima, M., Novak, A. J., Witzig, T. E., & Ansell, S. M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59806 · Cited by 309 · see citing works

Myeloid Expression of Adenosine A2A Receptor Suppresses T and NK Cell Responses in the Solid Tumor Microenvironment

Cekic, C., Day, Y., Sağ, D., & Linden, J. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3583 · Cited by 305 · see citing works

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

Marabelle, A., Kohrt, H. E. K., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J. A., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci73340 · Cited by 304 · see citing works

Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

Khalili, J. S., Liu, S., Rodríguez-Cruz, T., Whittington, M., Wardell, S., Liu, C., Zhang, M., Cooper, Z. A., Frederick, D. T., Li, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1632 · Cited by 302 · see citing works

Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients

Parmiani, G., Castelli, C., Pilla, L., Santinami, M., Colombo, M. P., & Rivoltini, L. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl158 · Cited by 300 · see citing works

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination

Derré, L., Rivals, J.-P., Jandus, C., Pastor, S., Rimoldi, D., Romero, P., Michielin, O., Olive, D., & Speiser, D. E. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40070 · Cited by 295 · see citing works

Radiation and immunotherapy: a synergistic combination

Kalbasi, A. K., June, C. H., Haas, N. B., & Vapiwala, N. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69219 · Cited by 285 · see citing works

Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells

Dardalhon, V., Anderson, A. C., Kármán, J., Apétoh, L., Chandwaskar, R., Lee, D. H., Cornejo, M., Nishi, N., Yamauchi, A., Quintana, F. J., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903275 · Cited by 278 · see citing works

PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells

Wang, W., Lau, R., Yu, D., Zhu, W., Korman, A. J., & Weber, J. S. (2009) · International Immunology · doi:10.1093/intimm/dxp072 · Cited by 277 · see citing works

Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies

Verbrugge, I., Hagekyriakou, J., Sharp, L. L., Gallí, M., West, A. C., McLaughlin, N. M., Duret, H., Yagita∥, H., Johnstone, R. W., Smyth, M. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0210 · Cited by 275 · see citing works

Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses

Yang, X., Zhang, X., Fu, M. L., Weichselbaum, R. R., Gajewski, T. F., Guo, Y., & Fu, Y. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.004 · Cited by 269 · see citing works

CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice

Wang, L., Fan, J., Thompson, L. F., Zhang, Y., Shin, T., Curiel, T. J., & Zhang, B. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45559 · Cited by 262 · see citing works

Eradication of established tumors in mice by a combination antibody-based therapy

Uno, T., Takeda, K., Kojima, Y., Yoshizawa, H., Akiba, H., Mittler, R. S., Gejyo, F., Okumura, K., Yagita∥, H., & Smyth, M. J. (2006) · Nature Medicine · doi:10.1038/nm1405 · Cited by 257 · see citing works

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

Kavanagh, B., O'Brien, S., Lee, D., Hou, Y., Weinberg, V., Rini, B., Allison, J. P., Small, E. J., & Fong, L. (2008) · Blood · doi:10.1182/blood-2007-11-125435 · Cited by 256 · see citing works

Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation

Bald, T., Landsberg, J., Lopez-Ramos, D., Renn, M., Glodde, N., Jansen, P., Gaffal, E., Steitz, J., Tolba, R. H., Kalinke, U., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0458 · Cited by 256 · see citing works

Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk

Feng, M., Chen, J. Y., Weissman-Tsukamoto, R., Volkmer, J.-P., Ho, P. Y., McKenna, K. M., Cheshier, S. H., Zhang, M., Ring, N. G., Gip, P., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424907112 · Cited by 253 · see citing works

Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma

Ralph, C., Elkord, E., Burt, D. J., O'Dwyer, J. F., Austin, E. B., Stern, P. L., Hawkins, R. E., & Thistlethwaite, F. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2870 · Cited by 250 · see citing works

Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models

Flies, D. B., Wang, S., Xu, H., & Chen, L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100660 · Cited by 249 · see citing works

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

Wilson, N. S., Yang, B., Yang, A., Loeser, S., Marsters, S. A., Lawrence, D. A., Li, Y., Pitti, R. M., Tótpál, K., Yee, S. F., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.012 · Cited by 247 · see citing works

Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor

Mittal, D., Young, A., Stannard, K. A., Yong, M. C. R., Teng, M. W. L., Allard, B., Stagg, J., & Smyth, M. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0957 · Cited by 243 · see citing works

A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1

Ngiow, S. F., Young, A., Jacquelot, N., Yamazaki, T., Enot, D., Zitvogel, L., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1082 · Cited by 237 · see citing works

Surgery induced immunosuppression

Hogan, B. V., Peter, M. B., Shenoy, H. G., Horgan, K. J., & Hughes, T. A. (2010) · The Surgeon · doi:10.1016/j.surge.2010.07.011 · Cited by 229 · see citing works

Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms

Cioffi, M., Trabulo, S. M. D., Hidalgo, M. M., Costello, E., Greenhalf, W., Erkan, M., Kleeff, J. H., Sáinz, B., & Heeschen, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1399 · Cited by 228 · see citing works

Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 “Don't Eat Me” Signals

McCracken, M. N., Cha, A. C., & Weissman, I. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2520 · Cited by 225 · see citing works

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy

Kwon, E. D., Foster, B. A., Hurwitz, A. A., Madias, C., Allison, J. P., Greenberg, N. M., & Burg, M. B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15074 · Cited by 223 · see citing works

Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis

Ignatiadis, M., Singhal, S. K., Desmedt, C., Haibe‐Kains, B., Criscitiello, C., André, F., Loi, S., Piccart, M. J., Michiels, S., & Sotiriou, C. P. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5624 · Cited by 218 · see citing works

CD73-Deficient Mice Are Resistant to Carcinogenesis

Stagg, J., Beavis, P. A., Divisekera, U., Liu, M. C. P., Möller, A., Darcy, P. K., & Smyth, M. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0420 · Cited by 211 · see citing works

HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function

Zhao, R., Chinai, J. M., Buhl, S., Scandiuzzi, L., Ray, A., Jeon, H., Ohaegbulam, K. C., Ghosh, K., Zhao, A., Scharff, M. D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303524110 · Cited by 204 · see citing works

Nuclear factor kappa B–mediated CD47 up‐regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice

Lo, J. H. T., Lau, E. Y.-T., Ching, R. H. H., Cheng, B. Y.-L., Ma, M. K. F., Ng, I. O., & Lee, T. K. (2015) · Hepatology · doi:10.1002/hep.27859 · Cited by 199 · see citing works

A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

Herbst, R. S., Gordon, M. S., Fine, G. D., Sosman, J. A., Soria, J., Hamid, O., Powderly, J. D., Burris, H. A., Mokatrin, A., Kowanetz, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3000 · Cited by 191 · see citing works

Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery

Predina, J. D., Eruslanov, E. B., Judy, B. F., Kapoor, V., Cheng, G., Wang, L.-C., Sun, J., Moon, E. K., Fridlender, Z. G., Albelda, S. Μ., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211850110 · Cited by 188 · see citing works

B7-H5 costimulates human T cells via CD28H

Zhu, Y., Yao, S., Iliopoulou, B. P., Han, X. N., Augustine, M. M., Xu, H., Phennicie, R., Flies, S. J., Broadwater, M., Ruff, W. E., et al. (2013) · Nature Communications · doi:10.1038/ncomms3043 · Cited by 184 · see citing works

Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street

Barrett, D. M., Grupp, S. A., & June, C. H. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500751 · Cited by 180 · see citing works

Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase

Inozume, T., Yaguchi, T., Furuta, J., Harada, K., Kawakami, Y., & Shimada, S. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.404 · Cited by 172 · see citing works

FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities

Nimmerjahn, F., Gordan, S., & Lux, A. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.04.005 · Cited by 171 · see citing works

Role of T lymphocytes in tumor response to radiotherapy

Demaria, S., & Formenti, S. C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00095 · Cited by 171 · see citing works

Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein

Janakiram, M., Chinai, J. M., Fineberg, S., Fiser, A., Montagna, C., Medavarapu, R., Castano, E., Jeon, H., Ohaegbulam, K. C., Zhao, R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1495 · Cited by 152 · see citing works

Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor

Waickman, A. T., Alme, A., Senaldi, L., Zarek, P. E., Horton, M. R., & Powell, J. D. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1155-7 · Cited by 151 · see citing works

Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma

Dovedi, S. J., Melis, M. H. M., Wilkinson, R. W., Adlard, A. L., Stratford, I. J., Honeychurch, J., & Illidge, T. (2012) · Blood · doi:10.1182/blood-2012-05-432393 · Cited by 145 · see citing works

The immune contexture of primary and metastatic human tumours

Giraldo, N. A., Becht, É., Remark, R., Damotte, D., Sautès‐Fridman, C., & Fridman, W. H. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.001 · Cited by 140 · see citing works

An NKp30-Based Chimeric Antigen Receptor Promotes T Cell Effector Functions and Antitumor Efficacy In Vivo

Zhang, T., Wu, M.-R., & Sentman, C. L. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103495 · Cited by 138 · see citing works

Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types

Ascierto, P. A., Kalos, M. D., Schaer, D., Callahan, M. K., & Wolchok, J. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2982 · Cited by 138 · see citing works

The coming of age of engineered multivalent antibodies

Nuñez‐Prado, N., Compte, M., Harwood, S. L., Álvarez-Méndez, A., Lykkemark, S., Sanz, L., & Álvarez‐Vallina, L. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.013 · Cited by 136 · see citing works

Blocking IDO activity to enhance anti-tumor immunity

Munn, D. H. (2012) · Frontiers in Bioscience-Elite · doi:10.2741/e414 · Cited by 136 · see citing works

Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques

Keler, T., Halk, E., Vitale, L. A., O’Neill, T., Blanset, D. L., Lee, S., Srinivasan, M., Graziano, R. F., Davis, T. A., Lönberg, N., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.6251 · Cited by 134 · see citing works

Vemurafenib reverses immunosuppression by myeloid derived suppressor cells

Schilling, B., Sucker, A., Griewank, K., Zhao, F., Weide, B., Görgens, A., Giebel, B., Schadendorf, D., & Paschen, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28168 · Cited by 124 · see citing works

A balance of interleukin-12 and -23 in cancer

Ngiow, S. F., Teng, M. W. L., & Smyth, M. J. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.07.004 · Cited by 116 · see citing works

Why does cytotoxic chemotherapy cure only some cancers?

Savage, P. M., Stebbing, J., Bower, M., & Crook, T. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1260 · Cited by 115 · see citing works

Blocking IDO activity to enhance anti-tumor immunity

David, H. M. (2011) · Frontiers in Bioscience-Elite · doi:10.2741/414 · Cited by 114 · see citing works

Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo

Li, F., & Ravetch, J. V. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319502110 · Cited by 109 · see citing works

TLR7 Promotes Tumor Progression, Chemotherapy Resistance, and Poor Clinical Outcomes in Non–Small Cell Lung Cancer

Chatterjee, S., Crozet, L., Damotte, D., Iribarren, K., Schramm, C., Alifano, M., Mansuet‐Lupo, A., Cherfils‐Vicini, J., Goc, J., Katsahian, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2698 · Cited by 106 · see citing works

Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy

Johnson, D. B., Wallender, E. K., Cohen, D. N., Likhari, S. S., Zwerner, J. P., Powers, J. G., Shinn, L., Kelley, M. C., Joseph, R. W., & Sosman, J. A. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0092 · Cited by 104 · see citing works

Bevacizumab: overview of the literature

Braghiroli, M. I., Sabbaga, J., & Hoff, P. M. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.13 · Cited by 101 · see citing works

STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice

Wang, Z., & Celis, E. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1713-5 · Cited by 97 · see citing works

Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer

Guo, Z., Cheng, D., Xia, Z., Luan, M., Wu, L., Wang, G., & Zhang, S. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-215 · Cited by 94 · see citing works

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab

Eroglu, Z., Kim, D. W., Wang, X., Camacho, L. H., Chmielowski, B., Seja, E., Villanueva, A., Ruchalski, K. L., Glaspy, J. A., Kim, K. B., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.012 · Cited by 83 · see citing works

Structure and Cancer Immunotherapy of the B7 Family Member B7x

Jeon, H., Vigdorovich, V. I., Garrett-Thomson, S. C., Janakiram, M., Ramagopal, U. A., Abadi, Y. M., Lee, J. S., Scandiuzzi, L., Ohaegbulam, K. C., Chinai, J. M., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.09.053 · Cited by 76 · see citing works

Radiotherapy Complements Immune Checkpoint Blockade

Ngiow, S. F., McArthur, G. A., & Smyth, M. J. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.015 · Cited by 75 · see citing works

Understanding the tumor immune microenvironment (TIME) for effective therapy

Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145 · see citing works

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · see citing works

Molecular therapies and precision medicine for hepatocellular carcinoma

Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,948 · see citing works

Cancer immunoediting and resistance to T cell-based immunotherapy

O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759 · see citing works

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664 · see citing works

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works

Mechanisms of resistance to immune checkpoint inhibitors

Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383 · see citing works

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,394 · see citing works

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer

Dienstmann, R., Vermeulen, L., Guinney, J., Kopetz, S., Tejpar, S., & Tabernero, J. M. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.126 · Cited by 1,038 · see citing works

Breast cancer: Biology, biomarkers, and treatments

Barzaman, K., Karami, J., Zarei‐Behjani, Z., Hosseinzadeh, A., Kazemi, M. H., Moradi‐Kalbolandi, S., Safari, E., & Farahmand, L. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106535 · Cited by 986 · see citing works

Second near-infrared photothermal materials for combinational nanotheranostics

Xu, C., & Pu, K. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00664e · Cited by 941 · see citing works

Phagocytosis checkpoints as new targets for cancer immunotherapy

Feng, M., Jiang, W., Kim, B. Y. S., Zhang, C. C., Fu, Y., & Weissman, I. L. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0183-z · Cited by 914 · see citing works

Neoantigen vaccine: an emerging tumor immunotherapy

Miao, P., Mo, Y., Wang, Y., Wu, P., Zhang, Y., Xiong, F., Guo, C. J., Wu, S., Li, Y., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1055-6 · Cited by 701 · see citing works

Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency

Li, Z., Lai, X., Fu, S., Ren, L. F., Cai, H., Zhang, H., Gu, Z., Ma, X., & Luo, K. (2022) · Advanced Science · doi:10.1002/advs.202201734 · Cited by 688 · see citing works

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

Derosa, L., Routy, B., Thomas, A. M., Iebba, V., Zalcman, G., Friard, S., Mazieres, J., Audigier-Valette, C., Moro-Sibilot, D., Goldwasser, F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01655-5 · Cited by 685 · see citing works

<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0833 · Cited by 594 · see citing works

Resistance to PD1/PDL1 checkpoint inhibition

O’Donnell, J. S., Long, G. V., Scolyer, R. A., Teng, M. W. L., & Smyth, M. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.007 · Cited by 574 · see citing works

Regulatory circuits of T cell function in cancer

Speiser, D. E., Ho, P., & Verdeil, G. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.80 · Cited by 559 · see citing works

TIGIT as an emerging immune checkpoint

Harjunpää, H., & Guillerey, C. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13407 · Cited by 552 · see citing works

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses

Moynihan, K. D., Opel, C. F., Szeto, G. L., Tzeng, A., Zhu, E. F., Engreitz, J., Williams, R. T., Rakhra, K., Zhang, M. H., Rothschilds, A. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4200 · Cited by 519 · see citing works

Tumor Microenvironment‐Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade

Zhou, F., Feng, B., Yu, H., Wang, D., Wang, T., Ma, Y., Wang, S., & Li, Y. (2019) · Advanced Materials · doi:10.1002/adma.201805888 · Cited by 503 · see citing works

Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)

Katoh, M. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4129 · Cited by 467 · see citing works

Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy

Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2020) · Advanced Materials · doi:10.1002/adma.202004788 · Cited by 452 · see citing works

Resistance Mechanisms to Anti-PD Cancer Immunotherapy

Vesely, M. D., Zhang, T., & Chen, L. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-070621-030155 · Cited by 468 · see citing works

Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti–PD-1 for tumor abrogation

Kaplanov, I., Carmi, Y., Kornetsky, R., Shemesh, A., Shurin, G. V., Shurin, M., Dinarello, C., Voronov, E., & Apte, R. (2018) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1812266115 · Cited by 404 · see citing works

Is autoimmunity the Achilles' heel of cancer immunotherapy?

June, C. H., Warshauer, J. T., & Bluestone, J. A. (2017) · Nature Medicine · doi:10.1038/nm.4321 · Cited by 445 · see citing works

IDO1 in cancer: a Gemini of immune checkpoints

Zhai, L., Ladomersky, E., Lenzen, A. C., Nguyen, B., Patel, R., Lauing, K. L., Wu, M., & Wainwright, D. A. (2018) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.143 · Cited by 441 · see citing works

The spectrum of T cell metabolism in health and disease

Bantug, G. R., Galluzzi, L., Kroemer, G., & Hess, C. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.99 · Cited by 421 · see citing works

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

Mosely, S. I. S., Prime, J. E., Sainson, R. C. A., Koopmann, J., Wang, D. Y. Q., Greenawalt, D. M., Ahdesmaki, M. J., Leyland, R., Mullins, S., Pacelli, L., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0114 · Cited by 410 · see citing works

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

Grasso, C. S., Tsoi, J., Onyshchenko, M., Abril-Rodriguez, G., Ross-Macdonald, P., Wind-Rotolo, M., Champhekar, A., Medina, E., Torrejon, D. Y., Shin, D. S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.005 · Cited by 390 · see citing works

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Zhang, H., Liu, L., Liu, J., Dang, P., Hu, S., Yuan, W., Sun, Z., Liu, Y., & Wang, C. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01725-x · Cited by 399 · see citing works

Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses

Young, A., Ngiow, S. F., Barkauskas, D. S., Sult, E., Hay, C. M., Blake, S. J., Huang, Q., Liu, J., Takeda, K., Teng, M. W. L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.025 · Cited by 389 · see citing works

Signal pathways of melanoma and targeted therapy

Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 403 · see citing works

Bridging Bio–Nano Science and Cancer Nanomedicine

Björnmalm, M., Thurecht, K. J., Michael, M., Scott, A. M., & Caruso, F. (2017) · ACS Nano · doi:10.1021/acsnano.7b04855 · Cited by 382 · see citing works

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers

Sharma, A., Subudhi, S. K., Blando, J., Scutti, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0762 · Cited by 382 · see citing works

Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1

Guzik, K., Żak, K. M., Grudnik, P., Magiera‐Mularz, K., Musielak, B., Törner, R., Skalniak, Ł., Dömling, A. S. S., Dubin, G., & Holak, T. A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00293 · Cited by 380 · see citing works

PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux

O’Donnell, J. S., Massi, D., Teng, M. W. L., & Mandalà, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.015 · Cited by 382 · see citing works

Radiotherapy: Changing the Game in Immunotherapy

Demaria, S., Coleman, C. N., & Formenti, S. C. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.05.002 · Cited by 367 · see citing works

Harnessing tumor‐associated macrophages as aids for cancer immunotherapy

Li, X., Liu, R., Su, X., Pan, Y., Han, X., Shao, C., & Shi, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1102-3 · Cited by 364 · see citing works

Fibroblast growth factor receptors as treatment targets in clinical oncology

Katoh, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0115-y · Cited by 362 · see citing works

Recent Progresses in Phototherapy‐Synergized Cancer Immunotherapy

Ng, C. W., Li, J., & Pu, K. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201804688 · Cited by 352 · see citing works

Treatment of Advanced Melanoma in 2020 and Beyond

Jenkins, R. W., & Fisher, D. E. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.03.943 · Cited by 343 · see citing works

Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy

Pinter, M., & Jain, R. K. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5616 · Cited by 335 · see citing works

A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy

Mu, W., Chu, Q., Liu, Y., & Zhang, N. (2020) · Nano-Micro Letters · doi:10.1007/s40820-020-00482-6 · Cited by 332 · see citing works

Polymeric microneedles for transdermal protein delivery

Ye, Y., Yu, J., Wen, D., Kahkoska, A. R., & Gu, Z. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.015 · Cited by 325 · see citing works

PD-1/PD-L1 and immunotherapy for pancreatic cancer

Feng, M., Xiong, G., Cao, Z., Yang, G., Zheng, S., Song, X., You, L., Zheng, L., Zhang, T., & Zhao, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.006 · Cited by 315 · see citing works

Emerging Opportunities and Challenges in Cancer Immunotherapy

Whiteside, T. L., Demaria, S., Rodriguez-Ruiz, M. E., Zarour, H. M., & Melero, I. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0049 · Cited by 318 · see citing works

Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers—Response

Sharma, A., Subudhi, S. K., Blando, J. M., Vence, L. M., Wargo, J. A., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0402 · Cited by 314 · see citing works

Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer

Cords, L., Engler, S., Haberecker, M., Rüschoff, J. H., Moch, H., de Souza, N., & Bodenmiller, B. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.021 · Cited by 318 · see citing works

Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy

Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310 · see citing works

Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy

Phuengkham, H., Ren, L. F., Shin, I. W., & Lim, Y. T. (2019) · Advanced Materials · doi:10.1002/adma.201803322 · Cited by 304 · see citing works

Molecular and nanoengineering approaches towards activatable cancer immunotherapy

Zhang, C., & Pu, K. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00773c · Cited by 301 · see citing works

Immuno-Oncology: Emerging Targets and Combination Therapies

Marshall, H. T., & Djamgoz, M. B. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00315 · Cited by 299 · see citing works

Engineering strategies to enhance oncolytic viruses in cancer immunotherapy

Tian, Y., Xie, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00951-x · Cited by 304 · see citing works

A review of bispecific antibodies and antibody constructs in oncology and clinical challenges

Suurs, F. V., Hooge, M. N. L., de Vries, E. G. E., & de Groot, D. J. A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.006 · Cited by 291 · see citing works

A proteomic landscape of diffuse-type gastric cancer

Ge, S., Xia, X., Ding, C., Zhen, B., Zhou, Q., Feng, J., Yuan, J., Chen, R., Li, Y., Ge, Z., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03121-2 · Cited by 287 · see citing works

Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy via Immune Activation and Checkpoint Inhibition

Li, Y., Zhao, R., Cheng, K., Zhang, K., Wang, Y., Zhang, Y., Li, Y., Liu, G., Xu, J., Xu, J., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c03776 · Cited by 281 · see citing works

Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma

Baba, Y., Nomoto, D., Okadome, K., Ishimoto, T., Iwatsuki, M., Miyamoto, Y., Yoshida, N., & Baba, H. (2020) · Cancer Science · doi:10.1111/cas.14541 · Cited by 280 · see citing works

A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer

Liu, Z., Li, M., Jiang, Z., & Wang, X. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.01.011 · Cited by 275 · see citing works

TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma

Guillerey, C., Harjunpää, H., Carrié, N., Kassem, S., Teo, T., Miles, K., Krumeich, S., Weulersse, M., Cuisinier, M., Stannard, K., et al. (2018) · Blood · doi:10.1182/blood-2018-01-825265 · Cited by 300 · see citing works

Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment

Gao, Q., Feng, J., Liu, W., Wen, C., Wu, Y., Liao, Q., Zou, L., Sui, X., Xie, T., Zhang, J., et al. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114445 · Cited by 276 · see citing works

Nanoparticles with ultrasound-induced afterglow luminescence for tumour-specific theranostics

Xu, C., Huang, J., Jiang, Y., He, S., Zhang, C., & Pu, K. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00978-z · Cited by 275 · see citing works

Circular RNA vaccine in disease prevention and treatment

Niu, D., Wu, Y., & Lian, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01561-x · Cited by 273 · see citing works

Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity

Li, X.-Y., Moesta, A. K., Xiao, C., Nakamura, K., Casey, M., Zhang, H., Madore, J., Lepletier, A., Aguilera, A. R., Sundarrajan, A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0541 · Cited by 265 · see citing works

Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti–PD-1/PD-L1 immunotherapy

Noman, M. Z., Parpal, S., Van Moer, K., Xiao, M., Yu, Y., Arakelian, T., Viklund, J., De Milito, A., Hasmim, M., Andersson, M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax7881 · Cited by 255 · see citing works

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade

Jacquelot, N., Yamazaki, T., Roberti, M. P., Duong, C. P. M., Andrews, M. C., Verlingue, L., Ferrere, G., Becharef, S., Vétizou, M., Daillère, R., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0224-x · Cited by 256 · see citing works

Host tissue determinants of tumour immunity

Salmon, H., Remark, R., Gnjatic, S., & Mérad, M. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0125-9 · Cited by 258 · see citing works

Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?

Badalamenti, G., Fanale, D., Incorvaia, L., Barraco, N., Listì, A., Maragliano, R., Vincenzi, B., Calò, V., Iovanna, J., Bazan, V., et al. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.01.013 · Cited by 245 · see citing works

Cardiotoxicity of immune checkpoint inhibitors

Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 247 · see citing works

Hot and cold tumors: Immunological features and the therapeutic strategies

Wang, L., Geng, H., Liu, Y., Liu, L., Chen, Y., Wu, F., Liu, Z., Ling, S., Wang, Y., & Zhou, L. (2023) · MedComm · doi:10.1002/mco2.343 · Cited by 246 · see citing works

Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer

Buisseret, L., Garaud, S., de Wind, A., den Eynden, G. V., Boisson, A., Solinas, C., Gu‐Trantien, C., Naveaux, C., Lodewyckx, J., Duvillier, H., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1257452 · Cited by 238 · see citing works

Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review)

Katoh, M. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3689 · Cited by 247 · see citing works

Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8 + T cells

Wang, S., Campos, J. S., Gallotta, M., Gong, M., Crain, C., Naik, E., Coffman, R. L., & Guiducci, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608555113 · Cited by 231 · see citing works

Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies

Gujar, S. A., Pol, J. G., Kim, Y., Lee, P. W. K., & Kroemer, G. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.11.006 · Cited by 234 · see citing works

Exploiting innate immunity for cancer immunotherapy

Yi, M., Li, T., Niu, M., Mei, Q., Zhao, B., Chu, Q., Dai, Z., & Wu, K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01885-w · Cited by 236 · see citing works

A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models

Willingham, S. B., Ho, P. Y., Hotson, A. N., Hill, C. M., Piccione, E. C., Hsieh, J. Y., Liu, L., Buggy, J. J., McCaffery, I., & Miller, R. A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0056 · Cited by 221 · see citing works

Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration

Yang, K., Han, W., Jiang, X., Piffkó, A., Bugno, J., Han, C., Li, S., Liang, H. L., Xu, Z., Zheng, W., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01225-x · Cited by 223 · see citing works

Hepatocellular carcinoma in the era of immunotherapy

Sim, H., & Knox, J. J. (2017) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2017.10.007 · Cited by 216 · see citing works

Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy

Sato, K., Sato, N., Xu, B., Nakamura, Y., Nagaya, T., Choyke, P. L., Hasegawa, Y., & Kobayashi, H. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6843 · Cited by 215 · see citing works

Enhancing Triple Negative Breast Cancer Immunotherapy by ICG‐Templated Self‐Assembly of Paclitaxel Nanoparticles

Feng, B., Niu, Z., Hou, B., Zhou, L., Li, Y., & Yu, H. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201906605 · Cited by 215 · see citing works

Responsive biomaterials: optimizing control of cancer immunotherapy

Xue, L., Thatte, A. S., Mai, D., Haley, R. M., Gong, N., Han, X., Wang, K., Sheppard, N. C., June, C. H., & Mitchell, M. J. (2023) · Nature Reviews Materials · doi:10.1038/s41578-023-00617-2 · Cited by 214 · see citing works

Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges

Noman, M. Z., Hasmim, M., Lequeux, A., Xiao, M., Duhem, C., Chouaı̈b, S., Berchem, G., & Janji, B. (2019) · Cells · doi:10.3390/cells8091083 · Cited by 215 · see citing works

CSF1R inhibition prevents radiation pulmonary fibrosis by depletion of interstitial macrophages

Meziani, L., Mondini, M., Petit, B., Boissonnas, A., de Montpréville, V., Mercier, O. M., Vozenin, M., & Deutsch, É. (2018) · European Respiratory Journal · doi:10.1183/13993003.02120-2017 · Cited by 209 · see citing works

Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1

Roux, C., Jafari, S. M., Shinde, R. S., Duncan, G. S., Cescon, D. W., Silvester, J., Chu, M. F., Hodgson, K., Berger, T., Wakeham, A. C., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819473116 · Cited by 208 · see citing works

Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy

Emran, A. A., Chatterjee, A., Rodger, E. J., Tiffen, J. C., Gallagher, S. J., Eccles, M. R., & Hersey, P. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.004 · Cited by 205 · see citing works

Neutrophils in cancer

Treffers, L. W., Hiemstra, I. H., Kuijpers, T. W., van den Berg, T. K., & Matlung, H. L. (2016) · Immunological Reviews · doi:10.1111/imr.12444 · Cited by 204 · see citing works

Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy

Gao, J., Wang, W.-Q., Pei, Q., Lord, M. S., & Yu, H.-J. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0400-z · Cited by 203 · see citing works

Immunoregulatory functions of VISTA

Nowak, E. C., Lines, J. L., Varn, F. S., Deng, J., Sarde, A., Mabaera, R., Kuta, A., Mercier, I. L., Cheng, C., & Noelle, R. J. (2017) · Immunological Reviews · doi:10.1111/imr.12525 · Cited by 200 · see citing works

Trojan Horse nanotheranostics with dual transformability and multifunctionality for highly effective cancer treatment

Xue, X., Huang, Y., Bo, R., Jia, B., Wu, H., Yuan, Y., Wang, Z., Ma, Z., Jing, D., Xu, X., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06093-5 · Cited by 199 · see citing works

Inhibiting Metastasis and Preventing Tumor Relapse by Triggering Host Immunity with Tumor-Targeted Photodynamic Therapy Using Photosensitizer-Loaded Functional Nanographenes

Yu, X., Gao, D., Gao, L., Lai, J., Zhang, C., Zhao, Y., Zhong, L., Jia, B., Wang, F., Chen, X. S., et al. (2017) · ACS Nano · doi:10.1021/acsnano.7b04736 · Cited by 192 · see citing works

Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models

Leone, R. D., Sun, I.-M., Oh, M. H., Sun, I., Wen, J., Englert, J. M., & Powell, J. D. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2186-0 · Cited by 191 · see citing works

Biomedical polymers: synthesis, properties, and applications

Chen, W., Chen, Q., Chen, Q., Cui, C., Duan, S., Kang, Y., Liu, Y., Liu, Y., Muhammad, W., Shao, S., et al. (2022) · Science China Chemistry · doi:10.1007/s11426-022-1243-5 · Cited by 191 · see citing works

Engineered macrophages as near-infrared light activated drug vectors for chemo-photodynamic therapy of primary and bone metastatic breast cancer

Huang, Y., Guan, Z., Dai, X., Shen, Y., Qin, W., Ren, L., Jiang, J., Xiao, Z., Jiang, Y., Liu, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24564-0 · Cited by 182 · see citing works

Tumor-infiltrating lymphocytes: Warriors fight against tumors powerfully

Lin, B., Du, L., Li, H., Zhu, X. M., Cui, L., & Li, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110873 · Cited by 185 · see citing works

Genomic Approaches to Understanding Response and Resistance to Immunotherapy

Braun, D. A., Burke, K. P., & Allen, E. M. V. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0066 · Cited by 177 · see citing works

Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors

Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01363-8 · Cited by 176 · see citing works

Immunotherapies: Exploiting the Immune System for Cancer Treatment

Koury, J., Lucero, M., Cato, C., Chang, L., Geiger, J., Henry, D., Hernandez, J., Hung, F., Kaur, P., Teskey, G., et al. (2018) · Journal of Immunology Research · doi:10.1155/2018/9585614 · Cited by 180 · see citing works

IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma

Zhang, W., Liu, Y., Yan, Z., Yang, H., Sun, W. Y., Yao, Y., Chen, Y., & Jiang, R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000285 · Cited by 174 · see citing works

Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors

Wang, H., Najibi, A. J., Sobral, M. C., Seo, B. R., Lee, J. Y., Wu, D. T. S., Li, A. W., Verbeke, C. S., & Mooney, D. J. (2020) · Nature Communications · doi:10.1038/s41467-020-19540-z · Cited by 173 · see citing works

Necroptosis in Immuno-Oncology and Cancer Immunotherapy

Sprooten, J., Wijngaert, P. D., Vanmeerbeek, I., Martin, S., Vangheluwe, P., Schlenner, S., Krysko, D. V., Parys, J. B., Bultynck, G., Vandenabeele, P., et al. (2020) · Cells · doi:10.3390/cells9081823 · Cited by 169 · see citing works

Present and future of cancer immunotherapy: A tumor microenvironmental perspective (Review)

Yu, Y., & Cui, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.9219 · Cited by 78 · see citing works

Classifying Cancers Based on T-cell Infiltration and PD-L1

Teng, M. W. L., Ngiow, S. F., Ribas, A., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0255 · Cited by 1,412 · see citing works

Rational combinations of immunotherapeutics that target discrete pathways

Spranger, S., & Gajewski, T. F. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-16 · Cited by 74 · see citing works

Current Strategies to Enhance Anti-Tumour Immunity

Cook, K., Durrant, L. G., & Brentville, V. A. (2018) · Biomedicines · doi:10.3390/biomedicines6020037 · Cited by 15 · see citing works

Abstract SY07-01: New targets in combination cancer immunotherapies

Smyth, M. J. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-sy07-01 · Cited by 2 · see citing works